PMID- 30995142
OWN - NLM
STAT- MEDLINE
DCOM- 20191210
LR  - 20211204
IS  - 1520-5762 (Electronic)
IS  - 0363-9045 (Linking)
VI  - 45
IP  - 8
DP  - 2019 Aug
TI  - UNBS5162 as a novel naphthalimide holds efficacy in human gastric carcinoma cell 
      behaviors mediated by AKT/ERK signaling pathway.
PG  - 1306-1312
LID - 10.1080/03639045.2019.1607870 [doi]
AB  - Purpose: Studies have determined that UNBS5162, recognized as a new 
      naphthalimide, holds inhibitory effects in prostate and breast tumors; however, 
      its functional implication on gastric carcinoma is currently undetermined. Based 
      on this, this study designed to assess the functional role of it on human gastric 
      carcinoma and underlying mechanism of action. Methods: Cell counting kit-8 
      (CCK-8) assay, transwell assay, and flow cytometry were used to assess 
      capabilities of SGC-7901 cell proliferation, invasion/migration, and apoptosis, 
      respectively. Moreover, western blot was performed to determine the relative 
      expression of protein related to autophagy and protein kinase B 
      (AKT)/extracellular regulated protein kinases (ERK) signaling pathway. Results: 
      We found SGC-7901 cells proliferation, invasion, and migration were significantly 
      inhibited after treatment of UNBS5162. Moreover, the expression levels of 
      anti-apoptotic protein Bcl-2 decreased while the expression of pro-apoptotic 
      protein active caspase 3 and Bax increased concurrently after UNBS5162 
      stimulation. Further, upregulated LC3 II/I and Beclin-1 and downregulated P62 
      were induced by UNBS5162 addition. Mechanically, the ratios of 
      phosphorylated-(p-)AKT/AKT, p-mammalian target of rapamycin (mTOR)/mTOR, and 
      p-ERK/ERK were hampered by UNBS5162 application. Conclusion: UNBS5162 could 
      restrain gastric carcinoma cell proliferation, invasion, and migration, which 
      maybe induced by enhancement of apoptosis, autophagy manipulated through AKT/ERK 
      signaling pathway.
FAU - Li, Hong-Hai
AU  - Li HH
AD  - a Department of General Surgery , The Second Affiliated Hospital of Mudanjiang 
      Medical University , Mudanjiang , China.
FAU - Song, Xian-Xu
AU  - Song XX
AD  - a Department of General Surgery , The Second Affiliated Hospital of Mudanjiang 
      Medical University , Mudanjiang , China.
FAU - Liu, Bo
AU  - Liu B
AD  - a Department of General Surgery , The Second Affiliated Hospital of Mudanjiang 
      Medical University , Mudanjiang , China.
FAU - Yang, Wen-Ping
AU  - Yang WP
AD  - b Department of Medical Records Management , The Second Affiliated Hospital of 
      Mudanjiang Medical University , Mudanjiang , China.
LA  - eng
PT  - Journal Article
DEP - 20190524
PL  - England
TA  - Drug Dev Ind Pharm
JT  - Drug development and industrial pharmacy
JID - 7802620
RN  - 0 (Naphthalimides)
RN  - 0 (UNBS 5162)
RN  - 8W8T17847W (Urea)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Autophagy/drug effects
MH  - Carcinoma/*drug therapy/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Down-Regulation/drug effects
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Humans
MH  - MAP Kinase Signaling System/*drug effects
MH  - Naphthalimides/*pharmacology
MH  - Neoplasm Invasiveness/pathology
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction/drug effects
MH  - Stomach Neoplasms/*drug therapy/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Up-Regulation/drug effects
MH  - Urea/*analogs & derivatives/pharmacology
OTO - NOTNLM
OT  - AKT/ERK
OT  - UNBS5162
OT  - apoptosis
OT  - autophagy
OT  - gastric carcinoma
EDAT- 2019/04/18 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/04/18 06:00
PHST- 2019/04/18 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/04/18 06:00 [entrez]
AID - 10.1080/03639045.2019.1607870 [doi]
PST - ppublish
SO  - Drug Dev Ind Pharm. 2019 Aug;45(8):1306-1312. doi: 10.1080/03639045.2019.1607870. 
      Epub 2019 May 24.